There is a moment every Vancouver biotech founder knows. The term sheet arrives from a large pharma acquirer. The number is significant. The lawyers start calling. And then—increasingly—the founder says no.

It is not because the offer lacks value, but because they have calculated the potential of remaining independent.

Across Metro Vancouver’s life sciences sector, a structural shift is reshaping how local companies capture value from their intellectual property. Rather than selling outright to global pharma or large-cap biotech, a growing cohort of founders—particularly in oncology and genomics—is opting for licensing and royalty structures that keep the company intact, the team in place, and the upside compounding locally.

The trend is the product of a maturing IP base, a federal funding architecture that rewards independence, and a generation of founders who watched their predecessors sell early and spend the following decade watching acquirers extract the value they left behind.

The Numbers That Changed the Calculus

BC's life sciences sector employs approximately 18,000 people and generates more than $4 billion in annual revenues, according to Life Sciences BC. These figures reflect a sector with the critical mass to negotiate rather than simply accept acquisition.

Global pharma licensing deal values hit record highs in 2025, with royalty rates on oncology intellectual property averaging between 8 and 12 per cent—a range that, on a blockbuster drug, can generate more cumulative value than a single acquisition premium.

What's Driving the Shift

Three forces are converging to make licensing the rational choice for a specific class of Vancouver life sciences company.

The first is IP maturity. A decade ago, most local biotechs sold platform technology before it had proven clinical utility. Today, companies emerging from institutions like UBC, SFU, and the Centre for Drug Research and Development (CDRD), which has supported more than 100 drug discovery projects since its inception, arrive at licensing negotiations with validated mechanisms, clinical-stage assets, and often Phase II data.

The second force is non-dilutive federal capital. Programs including the National Research Council's Industrial Research Assistance Program (NRC-IRAP) have provided Metro Vancouver life sciences firms with the runway to reach value-inflection points without diluting equity.

The third force is founder-to-founder knowledge transfer. Vancouver's life sciences community is small enough that lessons travel quickly. Founders who sold companies in the 2015–2020 cycle, only to watch acquirers shelve promising pipelines or relocate R&D teams, have been candid with the next generation about their experiences. That institutional memory is now embedded in how early-stage companies approach exit optionality.

What Licensing Actually Looks Like

The licensing structures pursued by Vancouver companies vary. They range from co-development agreements with milestone payments and back-end royalties, to out-licensing specific geographic markets while retaining North American commercialisation rights, to platform licensing arrangements where a Vancouver company becomes the preferred supplier of a therapeutic modality to multiple global partners.

Innovate BC's commercialisation data points to an uptick in licensing activity among provincially supported life sciences firms over the past two years, consistent with the broader pattern founders and sector observers describe.

The Talent Argument

Ask any Vancouver life sciences founder why they chose licensing over an exit, and they will point to their team. Acquisitions are talent disruption events. Integration timelines create uncertainty, and acquirer culture often clashes with founder culture. Key scientists—the people who built the IP—frequently leave before the deal is finalized.

Licensing preserves the team. Senior researchers become equity holders in a company that continues to grow. This retention effect compounds; experienced scientists train junior researchers, who develop new IP, which generates new licensing opportunities. For a sector that consistently identifies talent availability as its primary constraint, keeping experienced teams together is a competitive advantage with direct revenue implications.

The Ecosystem Multiplier

When Vancouver biotechs stay independent, they become anchors—hiring locally, training locally, and attracting global attention to the region as a credible life sciences hub rather than a feeder system for foreign acquirers.

Canadian Venture Capital and Private Equity Association deal tracking shows the life sciences sector accounting for a growing share of active company-building activity in BC, as opposed to pure exit transactions—a signal that the licensing model is showing up in aggregate data.

The Risks

The licensing path requires clear-eyed assessment of trade-offs. Royalty income is contingent; if a pharma partner fails to commercialise an asset effectively, or if a competing therapy disrupts the market, royalty streams can underperform. Companies that remain independent must also manage the financing required to advance their own pipelines while navigating licensing relationships.

The founders succeeding in this space treat licensing not as a substitute for building a business, but as one revenue stream within a diversified commercial strategy. The royalty is the proof point, not the finish line.

The Bigger Picture

Vancouver has long faced criticism for lacking the ambition to build large companies. The biotech licensing shift suggests that the narrative is changing. Founders choosing royalties over acquisitions are betting that Vancouver's science is robust enough to be the partner of choice for global pharma. Increasingly, global pharma is agreeing.

For the ecosystem, this bet—sustained over time—is what transforms a promising cluster into a genuine hub. The compounding effect of independent companies, retained talent, and reinvested royalties is creating a new trajectory for the region's life sciences sector.